ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,697.80
3.20 (0.19%)
26 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.20 0.19% 1,697.80 1,696.40 1,696.80 1,701.00 1,686.40 1,695.20 7,755,918 16:35:19
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.17 69.84B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,694.60p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £69.84 billion. Gsk has a price to earnings ratio (PE ratio) of 14.17.

Gsk Share Discussion Threads

Showing 18051 to 18074 of 33075 messages
Chat Pages: Latest  723  722  721  720  719  718  717  716  715  714  713  712  Older
DateSubjectAuthorDiscuss
06/9/2018
08:05
Yes, except that, for new products/applications, one-to-one is still effective in playing a part in the launch process.
tradermichael
06/9/2018
08:02
clients do most of their orders on line now
days of sales reps are becoming redundant

doohoma3
06/9/2018
01:00
TM,No Retired just use IG.
garycook
05/9/2018
08:40
I'm with AJ Bell, do you work for IG, Gary?
tradermichael
04/9/2018
11:10
GlaxoSmithKline PLC (GSK.L)

Already an IG client? Log in to trade
SELL
1577.80
BUY
1578.20
0.6
-6.60pts (-0.42%)

High: 1593.4

Low: 1578.0
91% of client accounts are long on this market

garycook
02/9/2018
16:15
UK pharmaceuticals group GlaxoSmithKline (GSK) will begin production at a new factory in the UAE in 2020, according to the company’s general manager for the Gulf region.
In an interview with Gulf News, GSK regional general manager Sally Storey said that the company is “looking at options” for its UAE facility.
“It may be that we don’t build something, we may look [to go] through a partnership,” the newspaper quoted her as saying. “We are relatively advanced in that right now. We’re looking at about six products initially.”

tradermichael
01/9/2018
10:58
Cannot explain it either. At the bottom line of the upward trend channel right now ….. sorry, bad description (my performance last week also says I'm no chartist!)
tradermichael
31/8/2018
19:28
So an important AZN advanced biologics trial,TULIP 1 Phase III for Lupus, fails and the sector gets kicked, fine - but can someone explain to me why GSK got kicked even harder than AZN? AZN down 1.7% GSK down 2%. FFS.
romeike
31/8/2018
14:43
Ready for a bounce off the upward trend line?
tradermichael
30/8/2018
11:53
Liberum Capital lowered from buy to hold today but increased its target price from 1630p to 1700p ( just put on for you guys I don't hold any at the moment)
jpjohn1
30/8/2018
10:26
Super news...

"GSK's treatment for children with severe asthma receives EU approval"


Have to feel for Astra Zeneca though...
Positive news on T2 diabetes device offset by:

"The U.S. Food and Drug Administration said on Wednesday a serious genital infection has been reported in patients taking SGLT2 inhibitors, a certain class of diabetes drugs approved for AstraZeneca Plc and
several other firms."

Yikes!

fangorn2
30/8/2018
09:24
Yes I am collecting filters!
abdullla
30/8/2018
08:29
Abdul here as well when is he going to e u a site
doohoma3
30/8/2018
07:50
RTTNews) - GlaxoSmithKline (GSK, GSK.L) announced that the European Commission has granted marketing authorisation for Nucala (mepolizumab) as an add-on treatment for severe refractory eosinophilic asthma in paediatric patients aged six up to 17 years. As a result of the licence extension Nucala is now approved for use for severe refractory eosinophilic asthma in both adult and paediatric patients in the 31 European countries covered by the European Medicines Agency.
Nucala is the first and only approved biologic therapy for paediatric patients with severe asthma that targets interleukin-5, which plays an important role in regulating the function of eosinophils.

tradermichael
30/8/2018
07:43
Good timing
abdullla
30/8/2018
07:13
IN ... 3489 shares @ 1584.178p
tradermichael
29/8/2018
10:36
rikky - posted something on my thread - IMO it could move sharply either way in sterling terms. (Remain long at present).
alphorn
29/8/2018
10:35
Could see this treading water around the £16 mark for the next few months. Any other views, whether bullish or bearish?
rikky72
28/8/2018
07:04
thecashmoney
27 Aug '18 - 18:11 - 18028 of 18028 (Filtered)

tradermichael
27/8/2018
17:11
Check nuog ,well worth a look if you're looking for growth from low cap ,deal expected shortly .
thecashmoney
27/8/2018
17:10
Just do your own research and ignore the noise is my advice,it's quite obvious that NUOG /MFDEVCO is on the cusp of transformational news .Comms from the company via tweets says negotiations are drawing to a conclusion,last rns from chairman states it's progressing .Recent podcast designed to be non promotional imvho .Think of it like buying a car ,you don't tell the other parties how much you love it ,you say it needs new tyres , exhaust is on its way out etc ,you want the best deal possible . According to my research it's a win win win for all involved. OSX-3 owners want more from their asset , dommo current operators need cash revenue to raise to develop other assets.Mfdevco obviously will be truly transformational as the podcast states it will put mfdevco in a very forward position,with most of the steps allready completed,alot of money has already been spent and will put this company in a very advanced state compared to its current market capitalisation.CM
thecashmoney
25/8/2018
01:57
The new Barron's agrees with you TraderMichael. They think Shingrix could generate $2 billion annual sales by 2022.Quote:Shares of Glaxo have returned 21%, 13 percentage points more than the S&P 500 index, since we recommended them late last year.They still look cheap at 14 times this year's projected earnings. Investors have begun to recognize the company's new growth drivers, but still don't give it credit for its pipeline of products in development, according to UBS analyst Michael Leuchten. For shareholders, there's no hurry to sell.
richard xii
24/8/2018
14:28
Yes, they are putting a 1790p price on it.

Additionally, I think the potential for Shingrix has not been fully appreciated as well …. ;0)

tradermichael
24/8/2018
13:00
Berenberg Says Glaxo HIV Drug Cabotegravir Is UnderratedBerenberg reiterated its Buy rating on GlaxoSmithKline saying the drugmaker's Cabotegravir treatment has been under-appreciated by the market...
abdullla
Chat Pages: Latest  723  722  721  720  719  718  717  716  715  714  713  712  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com